The Experts below are selected from a list of 324 Experts worldwide ranked by ideXlab platform
Richard I. Christopherson - One of the best experts on this subject based on the ideXlab platform.
-
Cell surface phenotype profiles distinguish stable and progressive chronic lymphocytic leukemia
Leukemia & lymphoma, 2014Co-Authors: Pauline Y. Huang, Larissa Belov, Stephen P. Mulligan, Oliver Giles Best, Juhura G. Almazi, Zadie Davis, Aneela Majid, Martin J. S. Dyer, Dana Pascovici, Richard I. ChristophersonAbstract:Chronic lymphocytic leukemia (CLL) is clinically heterogeneous. While some patients have indolent disease for many years, 20 – 30% will progress and ultimately die of their disease. CLL may be classifi ed by the Rai or Binet staging system, mutational status of the immunoglobulin variable heavy-chain gene ( IGVH ), ZAP-70 overexpression, cytogenetic abnormalities (13q , 12, 11q , 17p ) and expression of several cell surface Antigens (CD38, CD49d) that correlate with risk of disease progression. However, none of these markers identify all cases of CLL at risk. In a recent review, we summarized those CD Antigens known to correlate with the prognosis of CLL. The present study has identifi ed surface profi les of CD Antigens that distinguish clinically progressive CLL from slow-progressive and stable CLL. Using an extended DotScan ™ CLL antibody microarray (Version 3; 182 CD antibodies), and with refi ned analysis of purifi ed CD19 B-cells, the following 27 CD Antigens were diff erentially abundant for progressive CLL: CD11a, CD11b, CD11c, CD18, CD19, CD20 (two epitopes), CD21, CD22, CD23, CD24, CD25, CD38, CD40, CD43, CD45, CD45RA, CD52, CD69, CD81, CD84, CD98, CD102, CD148, CD180, CD196 and CD270. The extensive surface profi les obtained provide disease signatures with an accuracy of 79.2%, a sensitivity of 83.9% and a specifi city of 72.5% that could provide the basis for a rapid test to triage patients with CLL according to probability of clinical progression and potential earlier requirement for treatment.
-
analysis of human liver disease using a cluster of differentiation CD antibody microarray
Liver International, 2012Co-Authors: Wassim Rahman, Larissa Belov, Pauline Huang, Jeremy S Chrisp, Peter M Stapelberg, F J Warner, David G Bowen, Richard I. Christopherson, Jacob GeorgeAbstract:BACKGROUND: A CD antibody microarray has been previously developed allowing semi-quantitative identification of greater than 80 CD Antigens on circulating leucocytes from peripheral blood samples. This assay, which uses a live cell-capture technique, enables an extensive leucocyte immunophenotype determination in a single analysis and to date this has been used successfully to characterise diseases including human leukaemias and HIV infection. AIMS: To determine CD antigen expression profiles for patients with various liver diseases and to look for preserved disease-specific signatures. METHODS: Three liver disease groups including hepatitis C (HCV) (n = 35), non-alcoholic steatohepatitis (NASH) (n = 21) and alcohol-related liver disease (n = 14) were compared with a normal group (n = 23). Hierarchal Clustering (HCL) and Principal Component Analysis (PCA) of the data revealed distinct binding patterns for patients with and without cirrhosis. RESULTS: Patients with cirrhosis and portal hypertension compared with those without cirrhosis had significantly reduced expression of several markers of T-cell function including CD45, CD8, CD28 and TCR α/β. Disease prediction algorithms based on the expression data were able to discriminate cirrhotics from non-cirrhotics with 71% overall success, which improved to 77% when only patients with HCV were considered. CONCLUSIONS: These results demonstrate disease-specific consensus patterns of expression of CD Antigens for patients with chronic liver disease, suggesting that the CD antibody array is a promising tool in the analysis of human liver disease, and with further refinement may have future research and clinical utility.
-
Surface profiles for subclassification of chronic lymphocytic leukemia.
Leukemia & lymphoma, 2012Co-Authors: Pauline Y. Huang, Larissa Belov, Stephen P. Mulligan, O. Giles Best, Richard I. ChristophersonAbstract:Chronic lymphocytic leukemia (CLL) has a variable clinical course. Some patients have stable disease while others progress and require treatment. Levels of several cluster of differentiation (CD) Antigens are known to correlate with prognosis and may be used to stratify patients according to risk. In this review, we summarize current information on surface CD Antigens found on CLL, their pathological significance and their detection using CD antibody microarrays. The use of extensive immunophenotypic patterns or surface profiles as disease signatures for CLL subclassification, prognosis and patient management is discussed with a focus on triaging patients with CLL with progressive disease.
-
Surface profi les for subclassifi cation of chronic lymphocytic leukemia
2012Co-Authors: Pauline Y. Huang, Larissa Belov, Stephen P. Mulligan, O. Giles Best, Richard I. ChristophersonAbstract:Chronic lymphocytic leukemia (CLL) has a variable clinical course. Some patients have stable disease while others progress and require treatment. Levels of several cluster of diff erentiation (CD) Antigens are known to correlate with prognosis and may be used to stratify patients according to risk. In this review, we summarize current information on surface CD Antigens found on CLL, their pathological signifi cance and their detection using CD antibody microarrays. The use of extensive immunophenotypic patterns or surface profi les as disease signatures for CLL subclassifi cation, prognosis and patient management is discussed with a focus on triaging patients with CLL with progressive disease.
-
colorectal cancer cell surface protein profiling using an antibody microarray and fluorescence multiplexing
Journal of Visualized Experiments, 2011Co-Authors: Jerry Zhou, Larissa Belov, Stephen Clarke, Charles Chan, Michael J Solomon, Richard I. ChristophersonAbstract:The current prognosis and classification of CRC relies on staging systems that integrate histopathologic and clinical findings. However, in the majority of CRC cases, cell dysfunction is the result of numerous mutations that modify protein expression and post-translational modification1. A number of cell surface Antigens, including cluster of differentiation (CD) Antigens, have been identified as potential prognostic or metastatic biomarkers in CRC. These Antigens make ideal biomarkers as their expression often changes with tumour progression or interactions with other cell types, such as tumour-infiltrating lymphocytes (TILs) and tumour-associated macrophages (TAMs). The use of immunohistochemistry (IHC) for cancer sub-classification and prognostication is well established for some tumour types2,3. However, no single ‘marker’ has shown prognostic significance greater than clinico-pathological staging or gained wide acceptance for use in routine pathology reporting of all CRC cases. A more recent approach to prognostic stratification of disease phenotypes relies on surface protein profiles using multiple 'markers'. While expression profiling of tumours using proteomic techniques such as iTRAQ is a powerful tool for the discovery of biomarkers4, it is not optimal for routine use in diagnostic laboratories and cannot distinguish different cell types in a mixed population. In addition, large amounts of tumour tissue are required for the profiling of purified plasma membrane glycoproteins by these methods. In this video we described a simple method for surface proteome profiling of viable cells from disaggregated CRC samples using a DotScan CRC antibody microarray. The 122-antibody microarray consists of a standard 82-antibody region recognizing a range of lineage-specific leukocyte markers, adhesion molecules, receptors and markers of inflammation and immune response5, together with a satellite region for detection of 40 potentially prognostic markers for CRC. Cells are captured only on antibodies for which they express the corresponding antigen. The cell density per dot, determined by optical scanning, reflects the proportion of cells expressing that antigen, the level of expression of the antigen and affinity of the antibody6. For CRC tissue or normal intestinal mucosa, optical scans reflect the immunophenotype of mixed populations of cells. Fluorescence multiplexing can then be used to profile selected sub-populations of cells of interest captured on the array. For example, Alexa 647-anti-epithelial cell adhesion molecule (EpCAM; CD326), is a pan-epithelial differentiation antigen that was used to detect CRC cells and also epithelial cells of normal intestinal mucosa, while Phycoerythrin-anti-CD3, was used to detect infiltrating T-cells7. The DotScan CRC microarray should be the prototype for a diagnostic alternative to the anatomically-based CRC staging system.
A N Barclay - One of the best experts on this subject based on the ideXlab platform.
-
Monoclonal antibodies to rat leukocyte surface Antigens, MHC Antigens, and immunoglobulins.
Current protocols in immunology, 2001Co-Authors: M J Puklavec, A N BarclayAbstract:The CD nomenclature used for human-leukocyte surface Antigens is now being widely applied to naming their homologs in other species. This appendix catalogs those CD Antigens that have been clearly defined in the rat. There are also many other Antigens defined in the rat, but only those for which good biochemical data are available, such as amino acid sequences, are given here. The most commonly used antibodies are summarized.
-
Current Protocols in Immunology - Monoclonal antibodies to rat leukocyte surface Antigens, MHC Antigens, and immunoglobulins.
Current Protocols in Immunology, 1999Co-Authors: M J Puklavec, A N BarclayAbstract:The CD nomenclature used for human-leukocyte surface Antigens is now being widely applied to naming their homologs in other species. This appendix catalogs those CD Antigens that have been clearly defined in the rat. There are also many other Antigens defined in the rat, but only those for which good biochemical data are available, such as amino acid sequences, are given here. The most commonly used antibodies are summarized.
Stephen P. Mulligan - One of the best experts on this subject based on the ideXlab platform.
-
Cell surface phenotype profiles distinguish stable and progressive chronic lymphocytic leukemia
Leukemia & lymphoma, 2014Co-Authors: Pauline Y. Huang, Larissa Belov, Stephen P. Mulligan, Oliver Giles Best, Juhura G. Almazi, Zadie Davis, Aneela Majid, Martin J. S. Dyer, Dana Pascovici, Richard I. ChristophersonAbstract:Chronic lymphocytic leukemia (CLL) is clinically heterogeneous. While some patients have indolent disease for many years, 20 – 30% will progress and ultimately die of their disease. CLL may be classifi ed by the Rai or Binet staging system, mutational status of the immunoglobulin variable heavy-chain gene ( IGVH ), ZAP-70 overexpression, cytogenetic abnormalities (13q , 12, 11q , 17p ) and expression of several cell surface Antigens (CD38, CD49d) that correlate with risk of disease progression. However, none of these markers identify all cases of CLL at risk. In a recent review, we summarized those CD Antigens known to correlate with the prognosis of CLL. The present study has identifi ed surface profi les of CD Antigens that distinguish clinically progressive CLL from slow-progressive and stable CLL. Using an extended DotScan ™ CLL antibody microarray (Version 3; 182 CD antibodies), and with refi ned analysis of purifi ed CD19 B-cells, the following 27 CD Antigens were diff erentially abundant for progressive CLL: CD11a, CD11b, CD11c, CD18, CD19, CD20 (two epitopes), CD21, CD22, CD23, CD24, CD25, CD38, CD40, CD43, CD45, CD45RA, CD52, CD69, CD81, CD84, CD98, CD102, CD148, CD180, CD196 and CD270. The extensive surface profi les obtained provide disease signatures with an accuracy of 79.2%, a sensitivity of 83.9% and a specifi city of 72.5% that could provide the basis for a rapid test to triage patients with CLL according to probability of clinical progression and potential earlier requirement for treatment.
-
Surface profiles for subclassification of chronic lymphocytic leukemia.
Leukemia & lymphoma, 2012Co-Authors: Pauline Y. Huang, Larissa Belov, Stephen P. Mulligan, O. Giles Best, Richard I. ChristophersonAbstract:Chronic lymphocytic leukemia (CLL) has a variable clinical course. Some patients have stable disease while others progress and require treatment. Levels of several cluster of differentiation (CD) Antigens are known to correlate with prognosis and may be used to stratify patients according to risk. In this review, we summarize current information on surface CD Antigens found on CLL, their pathological significance and their detection using CD antibody microarrays. The use of extensive immunophenotypic patterns or surface profiles as disease signatures for CLL subclassification, prognosis and patient management is discussed with a focus on triaging patients with CLL with progressive disease.
-
Surface profi les for subclassifi cation of chronic lymphocytic leukemia
2012Co-Authors: Pauline Y. Huang, Larissa Belov, Stephen P. Mulligan, O. Giles Best, Richard I. ChristophersonAbstract:Chronic lymphocytic leukemia (CLL) has a variable clinical course. Some patients have stable disease while others progress and require treatment. Levels of several cluster of diff erentiation (CD) Antigens are known to correlate with prognosis and may be used to stratify patients according to risk. In this review, we summarize current information on surface CD Antigens found on CLL, their pathological signifi cance and their detection using CD antibody microarrays. The use of extensive immunophenotypic patterns or surface profi les as disease signatures for CLL subclassifi cation, prognosis and patient management is discussed with a focus on triaging patients with CLL with progressive disease.
-
Cladribine and Fludarabine Nucleoside Change the Levels of CD Antigens on B-Lymphoproliferative Disorders.
International journal of proteomics, 2010Co-Authors: Carlos Cassano, Larissa Belov, Pauline Huang, Stephen P. Mulligan, Swetlana Mactier, Richard I. ChristophersonAbstract:The purine analogs, fludarabine nucleoside (FdA), and cladribine (CDA) (1 M, 24 hours), significantly changed the levels of some surface Antigens on the human B-cell lines MEC2 and Raji. Changes in the surface proteins were identified using a Cluster of Differentiation (CD) antibody microarray that captures live cells and confirmed by flow cytometry. For Raji cells, CDA up-regulated CD10, CD54, CD80, and CD86, with repression of CD22, while FdA up-regulated CD20, CD54, CD80, CD86 and CD95. For MEC2 cells, CDA up-regulated CD11a, CD20, CD43, CD45, CD52, CD54, CD62L, CD80, CD86, and CD95, but FdA had no effect. Up-regulation of particular CD Antigens induced on a B-cell lymphoproliferative disorder by a purine analog could provide targets for therapeutic antibodies with synergistic cell killing.
-
profiling CD Antigens on leukaemias with an antibody microarray
FEBS Letters, 2009Co-Authors: Nicole Barber, Larissa Belov, Adrian Woolfson, Stephen P. Mulligan, Richard I. ChristophersonAbstract:Cluster of differentiation (CD) Antigens are defined when a surface molecule found on some members of a standard panel of human cells reacts with at least one novel antibody, and there is good accompanying molecular data. Monoclonal antibodies to surface CD Antigens on leukocytes have been used for flow cytometry, and more recently to construct microarrays that capture live cells. These DotScanTM microarrays enable the rapid and highly parallel characterization of repertoires of CD Antigens whose expression patterns may be correlated with discrete leukaemia subtypes, or used to define biomarker ‘signatures’ for non-hematological diseases. DotScanTM with fluorescence multiplexing enables profiling of CD Antigens for minor subsets of cells, such as colorectal cancer cells and tumour-infiltrating lymphocytes from a surgical sample.
Larissa Belov - One of the best experts on this subject based on the ideXlab platform.
-
Cell surface phenotype profiles distinguish stable and progressive chronic lymphocytic leukemia
Leukemia & lymphoma, 2014Co-Authors: Pauline Y. Huang, Larissa Belov, Stephen P. Mulligan, Oliver Giles Best, Juhura G. Almazi, Zadie Davis, Aneela Majid, Martin J. S. Dyer, Dana Pascovici, Richard I. ChristophersonAbstract:Chronic lymphocytic leukemia (CLL) is clinically heterogeneous. While some patients have indolent disease for many years, 20 – 30% will progress and ultimately die of their disease. CLL may be classifi ed by the Rai or Binet staging system, mutational status of the immunoglobulin variable heavy-chain gene ( IGVH ), ZAP-70 overexpression, cytogenetic abnormalities (13q , 12, 11q , 17p ) and expression of several cell surface Antigens (CD38, CD49d) that correlate with risk of disease progression. However, none of these markers identify all cases of CLL at risk. In a recent review, we summarized those CD Antigens known to correlate with the prognosis of CLL. The present study has identifi ed surface profi les of CD Antigens that distinguish clinically progressive CLL from slow-progressive and stable CLL. Using an extended DotScan ™ CLL antibody microarray (Version 3; 182 CD antibodies), and with refi ned analysis of purifi ed CD19 B-cells, the following 27 CD Antigens were diff erentially abundant for progressive CLL: CD11a, CD11b, CD11c, CD18, CD19, CD20 (two epitopes), CD21, CD22, CD23, CD24, CD25, CD38, CD40, CD43, CD45, CD45RA, CD52, CD69, CD81, CD84, CD98, CD102, CD148, CD180, CD196 and CD270. The extensive surface profi les obtained provide disease signatures with an accuracy of 79.2%, a sensitivity of 83.9% and a specifi city of 72.5% that could provide the basis for a rapid test to triage patients with CLL according to probability of clinical progression and potential earlier requirement for treatment.
-
analysis of human liver disease using a cluster of differentiation CD antibody microarray
Liver International, 2012Co-Authors: Wassim Rahman, Larissa Belov, Pauline Huang, Jeremy S Chrisp, Peter M Stapelberg, F J Warner, David G Bowen, Richard I. Christopherson, Jacob GeorgeAbstract:BACKGROUND: A CD antibody microarray has been previously developed allowing semi-quantitative identification of greater than 80 CD Antigens on circulating leucocytes from peripheral blood samples. This assay, which uses a live cell-capture technique, enables an extensive leucocyte immunophenotype determination in a single analysis and to date this has been used successfully to characterise diseases including human leukaemias and HIV infection. AIMS: To determine CD antigen expression profiles for patients with various liver diseases and to look for preserved disease-specific signatures. METHODS: Three liver disease groups including hepatitis C (HCV) (n = 35), non-alcoholic steatohepatitis (NASH) (n = 21) and alcohol-related liver disease (n = 14) were compared with a normal group (n = 23). Hierarchal Clustering (HCL) and Principal Component Analysis (PCA) of the data revealed distinct binding patterns for patients with and without cirrhosis. RESULTS: Patients with cirrhosis and portal hypertension compared with those without cirrhosis had significantly reduced expression of several markers of T-cell function including CD45, CD8, CD28 and TCR α/β. Disease prediction algorithms based on the expression data were able to discriminate cirrhotics from non-cirrhotics with 71% overall success, which improved to 77% when only patients with HCV were considered. CONCLUSIONS: These results demonstrate disease-specific consensus patterns of expression of CD Antigens for patients with chronic liver disease, suggesting that the CD antibody array is a promising tool in the analysis of human liver disease, and with further refinement may have future research and clinical utility.
-
Surface profiles for subclassification of chronic lymphocytic leukemia.
Leukemia & lymphoma, 2012Co-Authors: Pauline Y. Huang, Larissa Belov, Stephen P. Mulligan, O. Giles Best, Richard I. ChristophersonAbstract:Chronic lymphocytic leukemia (CLL) has a variable clinical course. Some patients have stable disease while others progress and require treatment. Levels of several cluster of differentiation (CD) Antigens are known to correlate with prognosis and may be used to stratify patients according to risk. In this review, we summarize current information on surface CD Antigens found on CLL, their pathological significance and their detection using CD antibody microarrays. The use of extensive immunophenotypic patterns or surface profiles as disease signatures for CLL subclassification, prognosis and patient management is discussed with a focus on triaging patients with CLL with progressive disease.
-
Surface profi les for subclassifi cation of chronic lymphocytic leukemia
2012Co-Authors: Pauline Y. Huang, Larissa Belov, Stephen P. Mulligan, O. Giles Best, Richard I. ChristophersonAbstract:Chronic lymphocytic leukemia (CLL) has a variable clinical course. Some patients have stable disease while others progress and require treatment. Levels of several cluster of diff erentiation (CD) Antigens are known to correlate with prognosis and may be used to stratify patients according to risk. In this review, we summarize current information on surface CD Antigens found on CLL, their pathological signifi cance and their detection using CD antibody microarrays. The use of extensive immunophenotypic patterns or surface profi les as disease signatures for CLL subclassifi cation, prognosis and patient management is discussed with a focus on triaging patients with CLL with progressive disease.
-
colorectal cancer cell surface protein profiling using an antibody microarray and fluorescence multiplexing
Journal of Visualized Experiments, 2011Co-Authors: Jerry Zhou, Larissa Belov, Stephen Clarke, Charles Chan, Michael J Solomon, Richard I. ChristophersonAbstract:The current prognosis and classification of CRC relies on staging systems that integrate histopathologic and clinical findings. However, in the majority of CRC cases, cell dysfunction is the result of numerous mutations that modify protein expression and post-translational modification1. A number of cell surface Antigens, including cluster of differentiation (CD) Antigens, have been identified as potential prognostic or metastatic biomarkers in CRC. These Antigens make ideal biomarkers as their expression often changes with tumour progression or interactions with other cell types, such as tumour-infiltrating lymphocytes (TILs) and tumour-associated macrophages (TAMs). The use of immunohistochemistry (IHC) for cancer sub-classification and prognostication is well established for some tumour types2,3. However, no single ‘marker’ has shown prognostic significance greater than clinico-pathological staging or gained wide acceptance for use in routine pathology reporting of all CRC cases. A more recent approach to prognostic stratification of disease phenotypes relies on surface protein profiles using multiple 'markers'. While expression profiling of tumours using proteomic techniques such as iTRAQ is a powerful tool for the discovery of biomarkers4, it is not optimal for routine use in diagnostic laboratories and cannot distinguish different cell types in a mixed population. In addition, large amounts of tumour tissue are required for the profiling of purified plasma membrane glycoproteins by these methods. In this video we described a simple method for surface proteome profiling of viable cells from disaggregated CRC samples using a DotScan CRC antibody microarray. The 122-antibody microarray consists of a standard 82-antibody region recognizing a range of lineage-specific leukocyte markers, adhesion molecules, receptors and markers of inflammation and immune response5, together with a satellite region for detection of 40 potentially prognostic markers for CRC. Cells are captured only on antibodies for which they express the corresponding antigen. The cell density per dot, determined by optical scanning, reflects the proportion of cells expressing that antigen, the level of expression of the antigen and affinity of the antibody6. For CRC tissue or normal intestinal mucosa, optical scans reflect the immunophenotype of mixed populations of cells. Fluorescence multiplexing can then be used to profile selected sub-populations of cells of interest captured on the array. For example, Alexa 647-anti-epithelial cell adhesion molecule (EpCAM; CD326), is a pan-epithelial differentiation antigen that was used to detect CRC cells and also epithelial cells of normal intestinal mucosa, while Phycoerythrin-anti-CD3, was used to detect infiltrating T-cells7. The DotScan CRC microarray should be the prototype for a diagnostic alternative to the anatomically-based CRC staging system.
M J Puklavec - One of the best experts on this subject based on the ideXlab platform.
-
Monoclonal antibodies to rat leukocyte surface Antigens, MHC Antigens, and immunoglobulins.
Current protocols in immunology, 2001Co-Authors: M J Puklavec, A N BarclayAbstract:The CD nomenclature used for human-leukocyte surface Antigens is now being widely applied to naming their homologs in other species. This appendix catalogs those CD Antigens that have been clearly defined in the rat. There are also many other Antigens defined in the rat, but only those for which good biochemical data are available, such as amino acid sequences, are given here. The most commonly used antibodies are summarized.
-
Current Protocols in Immunology - Monoclonal antibodies to rat leukocyte surface Antigens, MHC Antigens, and immunoglobulins.
Current Protocols in Immunology, 1999Co-Authors: M J Puklavec, A N BarclayAbstract:The CD nomenclature used for human-leukocyte surface Antigens is now being widely applied to naming their homologs in other species. This appendix catalogs those CD Antigens that have been clearly defined in the rat. There are also many other Antigens defined in the rat, but only those for which good biochemical data are available, such as amino acid sequences, are given here. The most commonly used antibodies are summarized.